NEW YORK (GenomeWeb News) – SQI Diagnostics today announced a non-brokered private placement intended to raise C$3.76 million (US$3.72 million) in gross proceeds.

The Toronto-based microarray diagnostic firm said it plans to offer up to a little more than 5 million units at C$.75 per unit as part of the placement. Each unit will consist of one common share and one common share purchase warrant. Each warrant will entitle the holder to buy one common share at C$1.10 for up to two years after the date of issuance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.